These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21422239)

  • 1. Evaluation of safety and pharmacokinetics of sodium 2,2 dimethylbutyrate, a novel short chain fatty acid derivative, in a phase 1, double-blind, placebo-controlled, single-dose, and repeat-dose studies in healthy volunteers.
    Perrine SP; Wargin WA; Boosalis MS; Wallis WJ; Case S; Keefer JR; Faller DV; Welch WC; Berenson RJ
    J Clin Pharmacol; 2011 Aug; 51(8):1186-94. PubMed ID: 21422239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease.
    Kutlar A; Ataga K; Reid M; Vichinsky EP; Neumayr L; Blair-Britt L; Labotka R; Glass J; Keefer JR; Wargin WA; Berenson R; Perrine SP
    Am J Hematol; 2012 Nov; 87(11):1017-21. PubMed ID: 22887019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease.
    Kutlar A; Reid ME; Inati A; Taher AT; Abboud MR; El-Beshlawy A; Buchanan GR; Smith H; Ataga KI; Perrine SP; Ghalie RG
    Am J Hematol; 2013 Nov; 88(11):E255-60. PubMed ID: 23828223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease.
    Reid ME; El Beshlawy A; Inati A; Kutlar A; Abboud MR; Haynes J; Ward R; Sharon B; Taher AT; Smith W; Manwani D; Ghalie RG
    Am J Hematol; 2014 Jul; 89(7):709-13. PubMed ID: 24677033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia.
    Fucharoen S; Inati A; Siritanaratku N; Thein SL; Wargin WC; Koussa S; Taher A; Chaneim N; Boosalis M; Berenson R; Perrine SP
    Br J Haematol; 2013 May; 161(4):587-93. PubMed ID: 23530969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, tolerability, and pharmacokinetics of KNS-760704 (dexpramipexole) in healthy adult subjects.
    Bozik ME; Mather JL; Kramer WG; Gribkoff VK; Ingersoll EW
    J Clin Pharmacol; 2011 Aug; 51(8):1177-85. PubMed ID: 20959524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders.
    Perrine SP; Ginder GD; Faller DV; Dover GH; Ikuta T; Witkowska HE; Cai SP; Vichinsky EP; Olivieri NF
    N Engl J Med; 1993 Jan; 328(2):81-6. PubMed ID: 7677966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects.
    Sinha VP; Choi SL; Soon DK; Mace KF; Yeo KP; Lim ST; Howey DC
    J Clin Pharmacol; 2014 Jul; 54(7):792-9. PubMed ID: 24504686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended therapy with intravenous arginine butyrate in patients with beta-hemoglobinopathies.
    Sher GD; Ginder GD; Little J; Yang S; Dover GJ; Olivieri NF
    N Engl J Med; 1995 Jun; 332(24):1606-10. PubMed ID: 7753139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A first-in-man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM-1 receptor inhibition.
    Cuvier V; Lorch U; Witte S; Olivier A; Gibot S; Delor I; Garaud JJ; Derive M; Salcedo-Magguilli M
    Br J Clin Pharmacol; 2018 Oct; 84(10):2270-2279. PubMed ID: 29885068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
    Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
    Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety, tolerability, and pharmacokinetic profile of GSK2838232, a novel 2nd generation HIV maturation inhibitor, as assessed in healthy subjects.
    Johnson M; Jewell RC; Peppercorn A; Gould E; Xu J; Lou Y; Davies M; Baldwin S; Tenorio AR; Burke M; Jeffrey J; Johns BA
    Pharmacol Res Perspect; 2018 Jul; 6(4):e00408. PubMed ID: 29930812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
    Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
    CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of Ferric Pyrophosphate Citrate, a Novel Iron Salt, Administered Intravenously to Healthy Volunteers.
    Pratt RD; Swinkels DW; Ikizler TA; Gupta A
    J Clin Pharmacol; 2017 Mar; 57(3):312-320. PubMed ID: 27557937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, pharmacokinetics, and pharmacodynamics of CHF 3381, a novel N-methyl-D-aspartate antagonist, after single oral doses in healthy subjects.
    Tarral A; Dostert P; Guillevic Y; Fabbri L; Rondelli I; Mariotti F; Imbimbo BP
    J Clin Pharmacol; 2003 Aug; 43(8):901-11. PubMed ID: 12953347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single and multiple dose evaluation of a novel MetAP2 inhibitor: Results of a randomized, double-blind, placebo-controlled clinical trial.
    Malloy J; Zhuang D; Kim T; Inskeep P; Kim D; Taylor K
    Diabetes Obes Metab; 2018 Aug; 20(8):1878-1884. PubMed ID: 29577550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Butyrate-induced reactivation of the fetal globin genes: a molecular treatment for the beta-hemoglobinopathies.
    Perrine SP; Faller DV
    Experientia; 1993 Feb; 49(2):133-7. PubMed ID: 7680003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease.
    Atweh GF; Sutton M; Nassif I; Boosalis V; Dover GJ; Wallenstein S; Wright E; McMahon L; Stamatoyannopoulos G; Faller DV; Perrine SP
    Blood; 1999 Mar; 93(6):1790-7. PubMed ID: 10068649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxyurea-induced HbF production in anemic primates: augmentation by erythropoietin, hematopoietic growth factors, and sodium butyrate.
    McDonagh KT; Dover GJ; Donahue RE; Nathan DG; Agricola B; Byrne E; Nienhuis AW
    Exp Hematol; 1992 Nov; 20(10):1156-64. PubMed ID: 1385194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.